Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL versus PREMPRO PREMPHASE.
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL versus PREMPRO PREMPHASE.
LEVONORGESTREL AND ETHINYL ESTRADIOL vs PREMPRO/PREMPHASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levonorgestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and provides feedback inhibition on the hypothalamic-pituitary-ovarian axis, preventing follicular development and ovulation.
Prempro/Premphase contains conjugated estrogens (CE) and medroxyprogesterone acetate (MPA). Estrogens bind to estrogen receptors (ERα/ERβ), activating genomic and non-genomic signaling, promoting proliferation of estrogen-responsive tissues, and modulating lipid metabolism. MPA is a progestin that binds to progesterone receptors, antagonizing estrogen-induced endometrial hyperplasia and blunting estrogen effects on breast tissue. The combination suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
Oral, 1 tablet daily containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol, or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol, taken at the same time each day for 21 days followed by 7 placebo tablets, or continuous daily dosing as per product labeling.
Conjugated estrogens 0.625 mg/medroxyprogesterone acetate 2.5 mg (Prempro) or 0.625 mg/5 mg (Premphase) orally once daily.
None Documented
None Documented
Levonorgestrel: terminal half-life approximately 24-32 hours. Ethinyl estradiol: terminal half-life approximately 13-27 hours (mean ~17 hours). The half-lives are relevant for once-daily dosing, achieving steady state within 5-7 days.
Conjugated estrogens: 10-24 hours (terminal, prolonged in hepatic impairment). Medroxyprogesterone acetate: 12-17 hours (terminal).
Levonorgestrel and ethinyl estradiol are primarily eliminated via renal excretion (40-68% as metabolites) and fecal excretion (20-45%). Less than 1% is excreted unchanged.
Renal (90-95% as glucuronide and sulfate conjugates; <5% unchanged), biliary/fecal (5-10%).
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination